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Abstract
Background: Osteosarcoma is a high malignant neoplasm, and conflicting findings have been reported on the survival
and function recovery of osteosarcoma patients experiencing limb salvage or amputation. In the present study, we
compared limb salvage surgery (LSS) with amputation in clinical outcomes of osteosarcoma patients by a meta-analysis.
Methods: The survival rate of osteosarcoma patients was collected from research reports from CNKI, MEDLINE, EMBASE,
the Cochrane Database, and Google Scholar till April 30, 2016. The quality of including articles was evaluated by two
independent reviewers. Differences between patients undergoing limb salvage surgery and amputation were analyzed
based on postoperative survival rates.
Results: Ten articles were included according to selection criteria. There were 1343 patients in total from these studies.
Our results showed that there was no significant difference between limb salvage surgery and amputation according to
local recurrence; however, patients with limb salvage surgery had a higher 5-year overall survival.
Conclusions: LSS results in higher 5-year survival rates and better survival, while not increasing the risk of local
recurrence. This study provided more evidences to support limb salvage surgery as a considerable treatment of
osteosarcoma patients.
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Background
Osteosarcoma is one rare kind of malignant tumors
originated from mesenchymal tissue, which appears most
commonly in young men between the ages 10 and 30 [1].
Prior to neoadjuvant chemotherapy, amputations and
disarticulations were the dominant treatments for osteo-
sarcoma with a 5-year overall survival (OS) rate of only
about 20% [2]. Currently, osteosarcoma chemotherapy
mainly consists of five drugs, high-dose methotrexate
(HDMTX) with leucovorin rescue, doxorubicin (adriamy-
cin), cisplatin, ifosfamide, and etoposide. With the use of
effective neoadjuvant chemotherapy in the 1970s, limb
salvage surgery (LSS) has been taken as a potential treat-
ment for osteosarcoma [3]. Usually, LSS has functional
and physiological advantages over traditional amputative
procedures when combined with neoadjuvant or adjuvant
chemotherapy [4].
Previous studies have shown that LSS is applicative for
localized osteosarcoma, while amputation is suitable for
aggressive malignant osteosarcoma [5, 6]. However, there
are still some surgeons holding an opposite view, consi-
dering that immediate and expanded resection of the tumor
will prevent the progression of fracture-induced disease.
Consequently, amputation is considered to be a better
option for osteosarcoma patients with pathologic
fracture [7, 8]. It has been reported that the risk of local
recurrence and the 5-year OS rate did not differ signifi-
cantly between LSS and amputation in osteosarcoma
patients with pathological fractures [9]. Han et al. has
reported that the risk of local recurrence and the 5-year
OS rate did not differ significantly between LSS and
amputation in osteosarcoma patients [10]. Other stud-
ies also reported a worse prognosis with osteosarcoma
associated with pathologic fractures [11].
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There were disputes on the survival and function recov-
ery between treatments of LSS and amputation in patients
with osteosarcoma [6, 12]. We conducted a meta-analysis
on survival and function in limb osteosarcoma patients
treated by LSS compared with amputation or rotation-
plasty [13]. In addition, our study investigated whether
LSS improved survival based on 5-year rates and local
cancer recurrence in osteosarcoma patients with LSS or
amputation treatment [5, 14].
Through searching more abundant osteosarcoma litera-
ture, we conduct this meta-analysis to get a comprehen-
sive conclusion in osteosarcoma patients treated by LSS
and amputation. These results will help us to determine
the most appropriate method to treat osteosarcoma [15].
Methods
Literature search
MEDLINE, Cochrane, EMBASE, and Google Scholar
databases were searched for relevant data till April 30,
2016. The reference lists of relevant studies were also hand-
searched. Keywords used for searching included limb
surgery, salvage surgery, amputation, osteosarcoma, bone
cancer, recurrence, and metastasis occurrence.
Included studies
Studies were included if they were contrastive research
between LSS and amputation groups, patients with
osteosarcoma in their four limbs, and a mass of data in
regard to local recurrence or 5-year overall survival rate.
Exclusion standard is as follows: studies including data
related to LSS or amputation groups without a
comparison, case series with less than 20 total patients,
letters, case reports, editorials, or reviews [16].
Study selection and data extraction
Outcomes were collected from the articles by two authors
of our study. The authors made a structured table and then
collected all the data into a database. The following data
were extracted from articles according to the inclusion
criteria: the name of the first author, year of publication,
design scheme, number of patients in each group, patients’
age and gender, local recurrence rates, and 5-year OS rates.
Any disagreement was resolved by sequential discussions
until an agreement was reached. Two reviewers independ-
ently assessed the quality of every included study according
to the Newcastle-Ottawa Scale (NOS).
Statistical analysis
The outcome of measurement used in our study was local
recurrence and 5-year overall survival rate, which were all
dichotomous data. We used the software of the Cochrane
Collaboration (ReviewManager5.2) to calculate odds ratios
(ORs) and 95% confidence intervals (CIs) for all outcomes.
Statistical heterogeneity among the included studies was
evaluated by the I2 tests. Statistically significant heterogen-
eity was defined as an I2 value >0.5 [9]. I2 illustrates the
percentage of the total variability in effect estimates
among trials that is due to heterogeneity rather than to
chance. A random effects model was selected for hetero-
geneous data; otherwise, a fixed effect model was selected.
Funnel plots were used to test the possibility of publica-
tion bias, which exhibited the intervention effect from the
Fig. 1 Flow chart of studies included and excluded
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individual study against the respective standard error. A
symmetrical plot represents no bias, and any asymmetry
of the plot suggests the existence of publication bias.
Results
Study selection and characterization
In the primary literature search, 147 relevant articles were
retrieved and 77 were excluded based on the exclusion
criteria (Fig. 1). The abstracts of the remaining 70 were
screened, and 45 were excluded based on the exclusion cri-
teria. After all the reviews of the remaining 25 studies, 15
were excluded due to lacking outcomes of interest (n = 10)
and duplication in the study population with other articles
(n = 5). In a word, a total of ten articles were included in
the meta-analysis. Characteristics of the studies are summa-
rized in Table 1, and outcomes are summarized in Table 2.
Local recurrence rate after surgery
All the ten studies reported the local recurrence rate. Our
studies reported no patients with local recurrence data for
either the amputation group or the LSS group. Therefore,
only ten studies with complete local recurrence rate data
were included in the analysis (Fig. 2). A fixed-effects
model of analysis was used [17]. There was no difference
in the local recurrence rate between LSS and amputation
(OR = 0.87, 95% CI 0.62–1.37, P = 0.42).
5-year overall survival and test of heterogeneity
Among these eligible studies, a total of ten studies with 5-
year survival rate data were included in the analysis (Fig. 3).
Totally, there was significant heterogeneity for the compari-
son of 5-year overall survival between the amputation
group and LSS group (Q test P value = 0.07, I2 = 43%). Ac-
cording to the result of stratification analysis, we explored
the source of heterogeneity from the subgroup analyses of
European (Fig. 4) (Q test P value = 0.41, I2 = 2%) and Asian
people (Q test P value = 0.009, I2 = 79%).
Sensitivity analysis
Sensitivity analyses indicated that included studies were
performed to determine the reliability of the results, with
each study removed in turn [17]. The direction and mag-
nitude of the combined estimates did not change mark-
edly with the exclusion of individual studies, indicating
that the results of the meta-analysis are reliable and sug-
gesting that the results of this meta-analysis are stable.
Table 1 Characteristics of the included studies
Ref. Study period Patient number Male/female Median age (range) Enneking stage Country
Ferrari et al. 1983–1986 127 (91/35) 72/55 15 (5–43) Stage IIB Austria
Bacci et al. 1986–1993 29 (25/4) 20/9 46 Stage IIB Italy
Edmonson et al. 1976–1980 38 (1/37) 24/14 17 (9–62) Stage IIB Austria
Gherlinzoni et al. 1983–1988 355 (239/116) – – Stage IIA Italy
Goorin et al. 1976–1989 74 (36/38) – – Stage IIA Austria
Zhang et al. 1981–1997 31 (17/14) 26/5 15 (7–42) Stage IIB China
Sha et al. 1989–2006 56 (35/21) – 18 (2–46) Stage IIA China
Niu et al. 1992–2001 189 (140/49) 125/64 18 (4–39) Stage IIB China
Bramer et al. 1983–2003 56 (44/12) 36/20 16 (3–36) Stage IIB America
Ferguson et al. 1989–2006 31 (19/12) 14/17 30 (11–32) Stage IIB America
Table 2 Outcomes of the included studies








Ferrari et al. 14 (2–96) (16/7) (36/23) (40/23) 130 (114–153)
Bacci et al. 22.9 (10–49) (2/1) (18/3) (6/4) 96 (60–144)
Edmonson et al. 22.2 (9–64) (0/11) (0/20) (1/7) 60 (31–74)
Gherlinzoni et al. 20 (5–88) (19/13) (67/56) (87/67) 64 (19–88)
Goorin et al. 20 (6–67) (17/10) (26/29) (21/24) 56 (7–120)
Zhang et al. 18 (9–62) (9/6) (11/10) (9/7) 62 (31–71)
Sha et al. 23 (11–43) (5/3) (17/6) (12/9) 55 (8–175)
Niu et al. 24 (9–64) (21/13) (56/34) (35/15) 24 (32–145)
Bramer et al. – (6/2) (30/8) – 54.7 (8–146)
Ferguson et al. – (2/0) (7/3) – –
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Publication bias
Funnel plots of the local recurrence rates and 5-year OS
rates were shown in Fig. 5. The results indicate that
there is no evidence of publication bias for each of the
two measures.
Discussion
Osteosarcoma is a kind of cancerous tumor in bones
[10]. Specifically, it is an aggressive malignant neoplasm
that arises from primitive transformed cells of mesen-
chymal origin (and thus a sarcoma) and that exhibits
osteoblastic differentiation and produces malignant oste-
oid. Osteosarcoma tends to affect regions around the
knee in 60% of cases, 15% around the hip, 10% at the
shoulder, and 8% in the jaw [18]. The tumor is solid,
hard, and irregular due to the tumor spicules of calcified
bone radiating in right angles.
Following the implementation of chemotherapy in the
1970s, the treatment of high-grade malignant osteosarcoma
has made an important progress [18]. Recently, most
chemotherapy regimens applied for osteosarcoma have
been based around four drugs: high-dose methotrexate
(HDMTX) with leucovorin rescue, doxorubicin (adriamy-
cin), cisplatin, and ifosfamide. These agents were integrated
into various chemotherapy protocols. The range of dosages
most commonly used are as follows: doxorubicin (cumula-
tive dose from 240 to 480 mg/m2), methotrexate (cumula-
tive dose from 48 to 168 g/m2) [19, 20], cisplatin
(cumulative dose from 480 to 600 mg/m2), and ifosfamide
(cumulative dose from 30 to 69 g/m2) [21].
Complete surgical resection, if feasible, remains essen-
tial for cure [22]. Current surgical strategies focus on re-
fining the nature and scope of resection to preserve
uninvolved tissues. Advances in imaging techniques and
positive effects of preoperative chemotherapy have led to
a major shift away from amputation to limb salvage
(conservative) surgery, which is expanded to limb sal-
vage (conservative) surgery, which is expanded to
around 80% of patients. Local recurrence rates of 2–3%
after amputation and 5–7% after conservative surgery
have been reported [22–24], while with no significant
differences. The incidence of local recurrence has been
closely related to the achieved surgical margins, with
only a wide margin being considered appropriate. Gener-
ally, for patients who achieved complete surgical remis-
sion with adequate margins, surgical margin width in
the bone did not correlate with the local recurrence rate.
With the improved efficacy of chemotherapy, the num-
ber of patients with osteosarcoma who received LSS in-
stead of amputation has significantly increased recently. It
was summarized that patients treated with LSS had a
similar local recurrence compared with those treated with
amputation. In the meta-analysis, we found that LSS had a
similar 5-year survival compared with those treated with
amputation. However, after excluding the three studies [9,
14, 25], which may be the main source of the heterogen-
eity and whose subjects were Asian, we found the hetero-
geneity reducing notably and P value (P = 0.0001) in the
comparison of LSS with amputation, which proved that 5-
year overall survival rate of patients treated with LSS was
Fig. 2 Forest plot of comparison. Local recurrence of LSS or amputation for the treatment of osteosarcoma
Fig. 3 Forest plot of comparison. 5-year overall survival of LSS or amputation for the treatment of osteosarcoma
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higher than those treated with amputation. Then in the
heterogeneity test, we found that there was apparent het-
erogeneity among all of the eligible studies. Thus, we
made a subgroup analysis, certifying that racial clas-
sification did lead to the heterogeneity. Funnel plot
did not show any evidence of publication bias.
Therefore, our results provide more powerful evidence
to support LSS as the treatment of osteosarcoma
patients.
We found that the LSS is better than amputation in
functional outcomes, which are consistent with other studies
[26, 27]. Johansen et al. [28] had reported notably higher
functional scores after LSS compared with amputation
respectively (P= 0.001). Another study which evaluated the
long-term physical function of the patients treated with LSS
found that amputees have poorer function as assessed by
the MSTS score [26]. However, a study by Mei et al. [22]
showed no difference in functional scores and QOL between
the two types of surgical management. More clinical trials
are needed to compare the functional recovery of different
surgical methods.
Some limitations of this meta-analysis should be men-
tioned. Firstly, the lack of detailed data form in original stud-
ies made it hard to adjust estimate by age, menopausal,
lifestyle, smoking, race, and so on, while more precise analysis
needed this kind of adjusting. Secondly, there was no detailed
data for functional recovery. Thirdly, not all control included
studies were in Hardy-Weinberg equilibrium (HWE) [28].
Otherwise, our meta-analysis also has some advantages.
Firstly, a systematic review of the association of survival
and function in limb osteosarcoma patients with LSS or
amputation treatment was statistically more powerful than
any single study. Secondly, all of the case-control studies
had a high quality and conformed to our inclusion criteria.
Conclusions
In the end, our meta-analysis emphasized that LSS can im-
prove survival of osteosarcoma patients with lower metastatic
occurrence and better survival, while not increasing the risk
of recurrence. Our meta-analysis also supported the hypoth-
esis that LSS can be a new option for osteosarcoma patients.
Fig. 4 Forest plot of comparison 5-year overall survival of LSS or amputation for the treatment of osteosarcoma with excluding three studies
Fig. 5 Funnel plot of comparison. a Local recurrence of LSS or amputation. b 5-year overall survival of LSS or amputation
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